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Abstract
Background: To improve risk factor management in diabetes, we need to support effective interactions between
patients and healthcare providers. Our aim is to develop and evaluate a treatment decision aid that offers
personalised information on treatment options and outcomes, and is intended to empower patients in taking a
proactive role in their disease management. Important features are: (1) involving patients in setting goals together
with their provider; (2) encourage them to prioritise on treatments that maximise relevant outcomes; and (3)
integration of the decision aid in the practice setting and workflow. As secondary aim, we want to evaluate the
impact of different presentation formats, and learn more from the experiences of the healthcare providers and
patients with the decision aid.
Methods and design: We will conduct a randomised trial comparing four formats of the decision aid in a 2×2
factorial design with a control group. Patients with type 2 diabetes managed in 18 to 20 primary care practices in
The Netherlands will be recruited. Excluded are patients with a recent myocardial infarction, stroke, heart failure,
angina pectoris, terminal illness, cognitive deficits, >65 years at diagnosis, or not able to read Dutch. The decision
aid is offered to the patients immediately before their quarterly practice consultation. The same decision
information will be available to the healthcare provider for use during consultation. In addition, the providers
receive a set of treatment cards, which they can use to discuss the benefits and risks of different options. Patients in
the control group will receive care as usual. We will measure the effect of the intervention on patient
empowerment, satisfaction with care, beliefs about medication, negative emotions, health status, prescribed
medication, and predicted cardiovascular risk. Data will be collected with questionnaires and automated extraction
from medical records in 6 months before and after the intervention.
Discussion: This decision aid is innovative in supporting patients and their healthcare providers to make shared
decisions about multiple treatments, using the patient’s data from electronic medical records. The results can
contribute to the further development and implementation of electronic decision support tools for the
management of chronic diseases.
Trial registration: Dutch Trial register NTR1942.
Keywords: Cardiovascular diseases, Diabetes mellitus, Type 2, Risk assessment, Decision-making, Electronic health
records, Primary healthcare, Choice behaviour, Decision support systems, Patient participation, Research design
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Background
Multifactorial treatment is recommended for patients with
type 2 diabetes mellitus to prevent and manage cardiovas-
cular and renal complications [1]. This implies that in
addition to glycemic control, strict management of blood
pressure, lipid levels, albuminuria, body weight, as well as
smoking cessation are considered important. Despite
improvements observed in many processes of diabetes
care, risk factor control in these patients remains subopti-
mal [2,3]. Active patient involvement is an important
element to achieve improvements in patient outcomes
[4,5]. Adequate management of chronic diseases requires
not only optimal performance from healthcare providers
but also sufficient understanding and motivation of
patients to start and sustain complicated medication and
lifestyle regimens [6,7]. Most patients with type 2 diabetes
have multiple conditions and risk factors which may
require prioritisation in treatment plans [8].
An important aspect is how to motivate both patients
and professionals to invest in the management of all risk
factors [9-11]. Time constraints, lack of support, patients’
motivation and treatment compliance, as well as discrep-
ancies between provider and patient perceptions have
been identified as reasons for not providing optimal care
in diabetes [10,12,13]. Healthcare providers perceive risk
communication as difficult and time-consuming, and want
additional tools to help them improve their patients’
understanding of risks [9,14-16]. There is a need for strat-
egies enhancing patient involvement in disease manage-
ment that are feasible to implement in routine care
[7,8,17]. Computer-based support systems and decision
aids have been developed to provide risk information and
treatment recommendations, and encourage shared
decision-making [18,19]. Their benefits in practice, how-
ever, appear to be limited [19,20]. They are not widely
used [21-23], and several barriers to their implementation
have been identified [24-26]. Important factors to success
or failure include good integration of the decision aid in
the electronic medical record (EMR) system, providing
personalised recommendations at the correct moment of
decision-making [24,26-28]. Especially, the focus on treat-
ment recommendations and not merely risk assessment
presentation appears to be critical. Interventions aimed at
improved monitoring of risk factors and calculating risk
scores may succeed in improving these processes of care
but seldom lead to improved clinical outcomes [29-32].
Interventions that include guidance on treatment options,
on the other hand, seem to be more successful in improv-
ing intermediate clinical outcomes, such as better
glycaemic and blood pressure control [33,34].
Shared decision-making and risk communication
Many medical decisions are still made with little input
from patients. To improve the quality and outcomes of
healthcare, shared decision-making is advocated [35].
Diabetes care is complex and the concept of multifactor-
ial risks may not be fully grasped by all patients. Patients
seem to focus primarily on blood glucose levels, and
may consider blood pressure or lipid control as less
important [36,37]. Experiments demonstrated that pro-
viding patients with additional information might stimu-
late physician-patient discussions concerning disease
management, and show promise in improving patient
outcomes [32,38-41]. Many patients appreciate getting
more insight in clinical management issues [42], and
report a better understanding of treatment goals after
receiving such information [43-45]. This can facilitate
patient-provider agreement on treatment goals [8,36,42].
In addition, it is expected to encourage better adherence
to treatment [7,15,41]. Engaging patients in their risk
assessment and treatment options before consultation
can augment more efficient interaction between patients
and professionals [15,46]. A proactive role of patients
may also result in a more timely adjustment of medica-
tion by their physician [38-40]. This last aspect is crucial
for achieving better clinical outcomes, since improving
only the disease monitoring process without changing
treatment decisions and behaviour is not likely to
improve clinical outcomes.
Theoretical framework and development of decision aid
To improve risk factor management in patients with
type 2 diabetes, we thus need to stimulate and support
effective interactions between patients and healthcare
providers. For this, the PORTDA-diab (Patient ORiented
Treatment Decision Aid for diabetes) project is set up.
In this project, primary care practices will use a novel
treatment decision aid focusing on shared goal-setting
and decision-making. The aid is to be used before and
during consultation by patients and their healthcare pro-
viders. This approach will have the potential to address
several elements considered important for productive
interactions as proposed in the chronic care model and
the model for shared decision-making [47,48]. These ele-
ments are: (1) clinical information system that facilitates
patient-provider conversations; (2) decision support that
promotes joint, well-informed goal setting and treatment
decisions; (3) proactive healthcare provider and patient,
and (4) self-management support through patient
empowerment and motivational counselling.
There are many decision aids for patients to support
their self-management of diabetes or cardiovascular risk
factors but only a few incorporate medication treatment
decisions [19,49]. There is debate about the best way to
inform patients regarding the benefits and risks of treat-
ment options, and engage them in setting treatment
goals [15,50]. So far, two types of treatment decision aids
for patients with diabetes or cardiovascular risks have
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been tested in practice [41,44,51]. The first type includes
the ‘diabetes medication choice’ and the ‘statin choice’
decision aids, which are intended to be used during con-
sultation and encourage patients to consider and voice their
views about medication options to the clinician [44,51-53].
They were found to be effective in involving patients in the
decision-making process but did not clearly improve adher-
ence or clinical outcomes [44,51,54]. They are paper-based
to make them usable in various consultation settings. The
disadvantage of this paper-based approach is that it
impedes automated tailoring to the patient’s medical his-
tory or situation. The other tested treatment decision aid is
a tailored computerised decision aid where patients can
enter clinical data, assess their cardiovascular risk, and
weigh their preferences for one or more treatment options
[55]. The user may examine interactively the effect of one
or more therapies and calculate adjusted risks for starting
aspirin, statins, antihypertensives, and smoking cessation.
This decision aid has been tested in a small study showing
some potential for reducing cardiovascular risk [41]. It is,
however, not integrated in the EMR system used by health-
care providers, which means that patients themselves must
provide the information to the aid.
Building on this existing knowledge and experience,
the PORTDA-diab decision aid was developed to include
the following key features:
 tailors the information on treatment goals and
options to the individual patient,
 addresses treatment decisions for multiple risk factors,
 presents pros and cons of all treatment options,
including doing nothing,
 facilitates comparisons across options,
 uses natural frequencies for outcome probabilities
and combines graphs and text with negative and
positive framing,
 asks patients to think about the treatment options,
 is used before and during consultation with the
healthcare provider,
 provides support at the correct moment for
decision-making,
 places the specific medication choice within the
consultation,
 is integrated in the electronic medical record
system, making full use of available information
while allowing for additional data entry or
correction,
 fits in the normal workflow of diabetes consultations
in primary care practice,
 is consistent with the evidence reflected in clinical
practice guidelines.
A step-wise development process was followed, as
recommended to enhance the quality of the decision aid
[56]. First, an inventory was made of what information
patients and providers need for making treatment deci-
sions. Next, the decision aid was reviewed in an inter-
active session with an expert panel of six patients with
diabetes. Several changes were made concerning the
information included and comparison with a reference
group, the inclusion of probing questions, and the
graphical and textual presentation. The revised decision
aid was further amended and approved by these subjects
through individual exchange. In addition, the aid was
reviewed by an independent expert on decision aids for
shared decision-making, and a textual review was con-
ducted by a master in Dutch linguistics. Two of the
researchers (PD, MD) not involved in the development
of the underlying algorithms subsequently tested the
content validity of the personalised information by
entering numerous combinations of input data and
reviewing the output. Finally, the usability of the
PORTDA-diab was field tested in 10 consultations with
diabetes patients and their healthcare providers in three
different practice settings. This resulted in several
changes to simplify navigation of the computer program.
A few technical issues were solved after this testing to
ensure good performance of the decision aid in all par-
ticipating practices, which use different EMR systems.
Objectives
The aim of this study is to evaluate positive and negative
effects of the novel patient-oriented treatment decision
aid (PORTDA-diab) for diabetes patients in primary
care. As secondary aims, we want to evaluate the
impact of different presentation formats, and learn
more from the experiences of healthcare providers
and patients when using the PORTDA-diab in daily
practice.
Research questions
1. What is the effect of the PORTDA-diab compared to
usual care on:
a) patient empowerment (primary outcome)
b) beliefs about treatment options
c) negative emotions
d) satisfaction with care
e) perceived health status
f ) treatment decisions
g) intermediate treatment outcomes and predicted
coronary heart disease (CHD) risk
2. To what extent is the effect modified by the
presentation medium or format:
a) comparing a paper-based with a computer version
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b) comparing a short version presenting treatment
effects on CHD risk with an extended version
presenting effects also on other outcomes which
can be of concern to patients
3. To what extent do healthcare providers and patients
adhere to the intended use of the decision aid, and
what are their experiences with using it in practice?
Methods
Design
We will evaluate the PORTDA-diab in a randomised
pre-post intervention trial using a 2×2 factorial interven-
tion design with a control group (see flowchart in
Figure 1). The factorial design is considered the most ef-
ficient method to study factors which may influence the
outcomes. The inclusion of a control group receiving
usual care but undergoing pre-post intervention meas-
urement will control for Hawthorne effects as well as for
independent effects or changes in the study population.
Study setting and participants
We will test the intervention in routine primary care set-
tings in The Netherlands. Primary care practices will be
recruited in the Groningen region where a diabetes dis-
ease management program has been implemented. Most
practices have a practice nurse who conducts quarterly
consultations with the diabetes patients. In The
Netherlands, it is common that primary care physicians
delegate these tasks of chronic care. Practice nurses are
trained to conduct practice examinations, risk assess-
ments, patient education, and counselling. They can
make medication treatment changes which have to be
approved by the physician. To ensure a minimum level
of communication skills training in all practices and in-
crease the study participation rate, providers are offered
a training session in motivational interviewing before the
study starts. In case they already have followed such a
course, they are offered €250 as alternative compensa-
tion for participation. In addition, all participants will re-
ceive a 2-h training in risk communication and an
instruction video with simulated consultations showing
‘good and bad examples’ of applying four basic principles
of risk communication, that is, to use natural frequen-
cies, use positive and negative phrasing, explicit uncer-
tainty, and be open and refrain from imposing options.
All practices use electronic medical record systems sup-
porting structured care protocols. Furthermore, all prac-
tices receive yearly performance reports as part of the
regional monitoring of diabetes care. We will thus evalu-
ate the additional effect of using the PORTDA-diab over
the current disease management program.
Eligible patients include people with type 2 diabetes
managed in primary care. Excluded are patients who had
a myocardial infarction within the preceding year,
experienced a stroke, suffer from heart failure, angina
Cluster randomisation 






























Figure 1 Flowchart of the PORTDA-diab study.
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pectoris, or have a terminal illness, and patients who
were above 65 years of age at diagnosis, because the cal-
culated risks and treatment goals in these patients are
not sufficiently evidence based. After identification of
eligible patients in the electronic medical record system,
the healthcare providers will confirm that the selected
patients satisfy these criteria. In addition, they will
exclude patients with dementia or cognitive deficits, who
are blind or not able to read Dutch, since such patients
are not expected to benefit from this type of interven-
tion. Practices will recruit patients by distributing infor-
mation packages containing an invitation letter,
information about the project, and an informed consent
form. Patients can contact the study coordinator for
additional information about the study or an independ-
ent general practitioner to discuss questions regarding
participation. Patients will be offered €10 in compensa-
tion for time spent to fill in the study questionnaires. In-
vitation letters will be followed up by telephone contact
by the research team when needed.
Treatment allocation
For pragmatic reasons, participating practices will be
randomly allocated to the paper-based or computer ver-
sion. This randomisation will be stratified by practice
size (below or above 2,500 patients) and organisation
(single or more primary care physicians), using a 1:1
computer-generated allocation sequence within the
strata (Figure 2).
Within each practice, consenting patients will be ran-
domised to receiving: (1) the PORTDA-diab presenting
only CHD outcomes; (2) the PORTDA-diab presenting
additional outcomes; or (3) the control group, using a
blockwise scheme to conceal the allocation process for
the healthcare provider. Although this design of rando-
mising patients within practices has the disadvantage of
potential contamination at provider level, it ensures that
variations in communication skills and practice organisa-
tion are balanced between the intervention and control
group. In addition, low participation and high drop-out
rates can be expected when practices are randomised to
a non-intervention control arm. It is not possible to use
the PORTDA-diab for other patients than the interven-
tion patients. It is, however, possible that providers will
use some of the aspects learned from working with the
novel approach in their usual care.
Intervention
The intervention consists of: (1) PORTDA-diab software
installed on a computer linked to the electronic medical
record system enabling up-to-date data retrieval of the
patient’s clinical situation and treatment status; (2) a set
of treatment cards which can be used during consult-
ation, summarising positive and side effects of available
treatment options; and (3) a short instruction protocol
for the healthcare provider about the decision aid and
treatment cards (Table 1). The decision aid offers perso-
nalised information on treatment goals and options to
patients immediately before they consult their healthcare
provider. The same information will be available to the
healthcare provider for further use during consultation.
In practices randomised to the computer version,
PORTDA-diab will be installed on a 17 inch laptop or
workstation that can be used by the patients. In practices
randomised to the paper-based version, a printed version
of the personalised information generated by the
PORTDA-diab software will be offered to the patients at
the practice. Intervention patients will be asked to come
to the practice 15 min in advance to go through this
additional information. All intervention patients should
receive the printed version at the end of the consult-
ation. The short version of the PORTDA-diab presents
treatment effects on reducing the risk of getting a myo-
cardial infarction, and comprises five pages or four
screens. The extended version covers seven pages or
eight screens, and presents treatment effects also on








Figure 2 Practice randomisation scheme.
Table 1 Instruction protocol for using the PORTDA-diab
and treatment cards
Before the consultation
• Start PORTDA software and retrieve information for scheduled patients
• Check whether the relevant patient’s data are available and up-to-date;
add or correct data when needed
• Print the information
During the consultation
• Start with open question on the patient’s opinion about the information
• Ask about emotions and/or cognitions related to the information
• Explore whether the patients already thought about consequences or
goals
• Support patient in thinking about treatment goals and options
• Ask patient for preferences regarding risks to target (first) and options
• Explicit treatment options where needed, and use treatment cards
when appropriate
• Do not force a decision but offer the option of a next consultation
when needed
• Ask whether the patients has other matters to discuss
• Conclude with clear action points (who will do what)
• Give paper version of the personalised information to the patient
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that are of concern to patients, that is, the risk of getting
a stroke, amputation, blindness, and renal failure
[9,57,58].
The information presented will be generated automat-
ically integrating routinely registered information from
the electronic medical records as well as evidence-based
information on diabetes treatment and outcomes as
summarised in the Dutch Primary Care Guidelines on
type 2 Diabetes [59]. The patient data are extracted real
time from the medical records but can be corrected or
completed by the provider when needed. The informa-
tion starts with a summary of the patient’s current situ-
ation and treatment (Figure 3). The patient’s risk
information is presented using bar graphs with simple
explanations of critical treatment goals and treatment
options [60]. Using the most recent information on the
patient’s risk factor levels and the UKPDS risk engine al-
gorithm [61], the patient’s overall risk of getting a myo-
cardial infarct within 5 years is calculated. This overall
risk will be presented in relation to potential improve-
ments and to a reference group (Figure 4). Such a refer-
ence is important since people can misperceive their
initial risk. The patient’s current risk is thus compared
to his/her expected risk when achieving the recom-
mended treatment goals for all risk factors (‘optimal
treatment’). At the same time, it is compared to the risk
of a patient with similar patient characteristics but with-
out diabetes, as calculated by the Framingham risk score
[62]. Should the Framingham risk score be higher than
the ‘optimal treatment’ risk, the former will be equated
to the latter. Next, the impact of achieving recom-
mended goals for separate risk factors will be presented
together with possible treatment options. Only risk
reductions are presented for risk factors that are not yet
at target level. These target levels are derived from the
Dutch Primacy Care Guidelines, being <53 mmol/mol
(<7%) for HbA1c, <140 mmHg for systolic blood pres-
sure, <2.5 mmol/L for LDL-cholesterol, and not smoking
[59]. Patients are explicitly encouraged to think about
which of the risk factors they prefer to address first. This
will enable prioritisation that may be needed when sev-
eral changes in treatment are required. In the short
version, only the impact on the risk of getting a myocar-
dial infarction is presented (Figure 5). In the extended
version, Figure 5 is replicated presenting the impact on
the other outcomes [63]. For myocardial infarction and
stroke, bars will be visible only if controlling the corre-
sponding risk factor will lead to an absolute risk reduc-
tion of 1% or more. For amputation, blindness, and renal
failure, bars will be visible at or above an absolute risk
reduction of 0.1%. These cut-points are chosen because
patients in the pilot phase mentioned that smaller reduc-
tions were not meaningful or relevant for them.
Treatment options and treatment cards
On the final page or screen, the treatment options are
summarised for those risk factors not yet at target level.
Both lifestyle and medication options can be presented.
The medication options are tailored to whether or not
the patient is already treated and/or is already receiving
maximum treatment. Maximum treatment is defined per
risk factor as: using insulin with or without additional
oral glucose-lowering medication, using three or more
antihypertensive drugs, using a statin at maximum dos-
age. Possible pros and cons of the options are sum-
marised. In addition, the healthcare providers can use a
set of treatment cards during consultation to discuss and
compare the benefits and risks of specific treatment
options (Figure 6).
Control group
Patients in the control group will receive care as usual,
including any education or information as deemed
necessary by the healthcare provider.
Effect modification
Effects of the decision aid may depend on characteristics
of the patients that affect their involvement, understand-
ing, and patient-provider communication about disease
management. Therefore, the following characteristics
will be included as possible modifying factors: age, gen-
der, educational level, socioeconomic status, duration of
diabetes, number and type of risk factors present,
co-morbidity, and number of drugs used.




HbA1c (averaged value for your glucose-levels)
Blood pressure
Total cholesterol
LDL-cholesterol (the ‘bad’ cholesterol)
HDL-cholesterol (the ‘good’ cholesterol)
Smoking status











metformin twice daily 500 mg
-
-
exercise and healthy diet 
Figure 3 Patient’s current situation and treatment status. Brief overview of information collected from the electronic medical record showing
the patient’s current situation and treatment.
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Outcome measures
In correspondence with the aim of the decision aid, our
primary outcome is empowerment of patients for mak-
ing shared decisions about setting and achieving treat-
ment goals [18]. As secondary outcomes, we include a
set of additional patient outcome and process of care
measures. These will provide insight into possible related
positive and negative effects and a better understan-








Your risk of getting a heart attack within the next 5 years
Your risk when target values are achieved for all risk factors
The risk of a similar person without diabetes
Figure 4 Bar graph showing the patient’s risk of getting a myocardial infraction. Shown are the patient’s current 5-year risk, the expected
risk when goals are achieved for all risk factors, and the risk of a similar person without diabetes.
What do you want?
What do you think about these risk factors? On the next page, several options are 
presented to counter these risks. What would you like to do? Which factor or factors 
do you want to deal with at this moment?
You can discuss this further with your health care provider to see which approach is 







Optimal approach Lower glucose Lower cholesterol Lower blood
pressure
Stop smoking
Your risk of getting a heart attack within the next 5 years
Your risk when target value is achieved for the referred factor only
Your risk when targets are achieved for all factors (optimal approach)
Figure 5 Bar graph showing the patient’s possible risk reductions for each risk factor with accompanying questions. Shown are the
patient’s possible risk reduction when all or each of the separate risk factors would reach the recommended target values. Below the graph the
accompanying questions asked in the decision aid are presented.
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Primary patient outcome:
a) diabetes empowerment (Diabetes Empowerment
Scale, subscale ‘Setting and Achieving Goals’ [64])
Secondary patient outcomes:
b)satisfaction with diabetes care (PEQ-D [65])
c) beliefs about medication (BMQ [66])
d)negative emotions (PAID [67])
e) health status (EQ-5D [68])
f ) predicted coronary heart disease risk [61])
Secondary process of care outcomes:
g)percentage of patients with (intensified)
antihypertensive treatment after insufficiently
controlled blood pressure levels
h)percentage of patients with (intensified) glucose-
lowering treatment after insufficiently controlled
HbA1c-levels
i) percentage of patients treated with lipid-lowering
drugs
j) percentage of patients with (micro)albuminuria
treated with a RAAS inhibitor
The Diabetes Empowerment Scale consists of three
subscales measuring different aspects of patient
empowerment: managing psychosocial aspects of dia-
betes (9 items); assessing dissatisfaction and readiness to
change (9 items); and setting and achieving goals (10
items) [64]. It has been translated into various languages,
and is considered a suitable tool in evaluating
empowerment-based education programmes. The sub-
scale on setting and achieving goals will be included as
primary outcome. The Patients’ Evaluation of Quality of
Diabetes Care is a 14-item scale assessing patients’ jud-
gements about the quality of their diabetes care, which
was found to be suitable for care delivered by physicians
as well as nurses [64]. The Beliefs about Medication
Questionnaire comprises two sections: the BMQ-
Specific, which assesses representations of medication
prescribed for personal use, and the BMQ-General,
which assesses beliefs about medicines in general [66]. It
has been translated into Dutch and used in many stud-
ies. The BMQ-Specific assesses beliefs about the neces-
sity of and concerns about prescribed medication. The
BMQ-General assesses beliefs that medicines are harm-
ful and overused. The Problem Areas in Diabetes (PAID)
is a 20-item questionnaire available in Dutch, assessing
diabetes-specific emotional functioning [67]. The EQ-5D
measures the general health status on five dimensions:
mobility, self-care, daily activities, pain and symptoms,
and negative emotions, and by a VAS-scale measuring
overall health status on a scale from 0 to 100 [68].
Process evaluation
In the post-intervention questionnaire, all patients will
be asked to complete a checklist, which assesses con-
tamination of control patients and exposure of interven-
tion patients to the intervention. Intervention patients
have to rate how easy or difficult they rate the decision
aid information on a five-point Likert scale. Patients
allocated to the computer version will in addition be
asked how easy or difficult they rate its navigation prop-








Sometimes (up to 10%):
muscle ache, painful joints, 
muscle weakness




Take pill once daily 
ACE-inhibitor
(e.g. lisinopril, ramipril, 
enalapril, perindopril)
Effect
Lowering of blood pressure 
Important side effects





Take pill once daily 
Healthy lifestyle
Effect
Possible lowering of blood 
pressure, glucose levels, 
cholesterol, weight and 
reduction of risk for other 
diseases
Important side effects
Difficult to change lifestyle
Use
Change diet, exercise 
several times weekly for 
around 30 minutes 
Figure 6 Example of treatment cards.
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consultation, they will be asked for a comparison of the
two versions. Providers’ experiences with the decision
aid will be assessed in qualitative interviews using a
topic list based on previous assessments regarding the
implementation of innovations in practice. To assess ad-
herence to the intended use (treatment fidelity), the
actual use of the decision aid before and during consul-
tations will be logged automatically in the computer ver-
sion. In addition, all providers will be asked to complete
a short checklist about the PORTDA-diab and the
(shared) decision-making process after each consultation
with an intervention patient.
Data collection
Patient data will be collected with structured question-
naires and automated extraction procedures from the
medical records. Patients’ empowerment, beliefs, satisfac-
tion, and perceptions will be measured using mailed sur-
veys that all patients will receive in the month before and
3 to 4 months after a scheduled quarterly consultation for
diabetes. Data on actual management and clinical out-
comes in the 6 months before and after the intervention
period will be collected from the Groningen Initiative to
Analyse Type 2 diabetes Treatment (GIANTT) database.
This GIANTT database includes longitudinal data col-
lected from primary care medical records using validated
automated extraction procedures [69].
Sample size
Sample size was calculated using the primary patient out-
come, that is, change in diabetes empowerment scale
(DES). Since there is no published minimum level of
change considered to be relevant [70], we used a change
of 0.2 in the DES score to estimate the sample size. With
an expected range in its baseline value of 3.2 to 4.0, this
represents a 5% to 6% change in the DES score. To be able
to detect an absolute change of 0.2 in the DES score, a
total of 150 patients per study arm is needed to achieve
80% power at 5% significance (standard deviation (sd)
=0.62). It is therefore estimated that we will need a sample
of 18 to 20 GPs, each with at least 20 to 30 participating
diabetes patients. This number is expected to be sufficient
to detect differences of 0.36 on the PEQ-D (sd=1.1), 6.5
on the PAID (sd=20.0), 0.26 on the BMQ (sd=0.8), and 5.0
on the UKPDS risk estimated (sd=15.5). These are all con-
servative sd estimates derived either from the original val-
idation studies or available data on the UKPDS risk scores
for the GIANTT population. Primary care practices in the
recruitment region have on average around 45 type 2 dia-
betes patients eligible for this study.
Statistical analysis
Descriptive statistics will be used to summarise demo-
graphic, clinical, and other patient measures. The primary
analysis will test pre-post intervention changes in patient
outcomes in the combined intervention group as com-
pared to the control group using Student t-test and Wil-
coxon’s two-sample statistics. Furthermore, we will
examine differences in primary and secondary outcomes
stratified by presentation format and medium in each
intervention arm. For the process of care outcomes, z-
approximation statistics will be used. Data will be analysed
on an intention-to-treat basis, and results of two-sided
tests between study arms will be regarded significant at
P<0.05. We will explore the influence of the practice on
the outcomes by multilevel modelling. Also, for hypothesis
generation, interactions will be tested to identify possible
factors at patient level that might modify the effect of the
intervention.
Ethical approval and trial registration
The study will be conducted in accordance with the
recommendations provided in the Dutch Code of con-
duct for health research. The medical ethics committee
of the University Medical Centre Groningen approved
the study (ARB number NL29042.042.09). The GIANTT
project and its data collection and database are regis-
tered at the CBP (College Bescherming Persoonsgege-
vens, number 1250778). The trial is registered at the
Dutch Trial register NTR1942 with the acronym
PORTDA-diab.
Discussion
The proposed study focuses on the much-needed trans-
lation of evidence-based diabetes care in real world set-
tings [71]. It focuses on patient empowerment and
patient-centred shared goal setting, which are considered
priority areas for further research. It builds upon previ-
ous behavioural and implementation research which
identified elements, such as proactive surveillance, pa-
tient involvement in setting realistic treatment goals and
strategies, outcomes-related processes, and use of clin-
ical information systems to improve the quality of care,
as some of the key characteristics of effective diabetes
management. There is growing evidence that active pa-
tient involvement improves diabetes care but the focus
has been mostly on dietary and glucose regulation issues.
Little attention has been given to involving patients in
the overall treatment decision-making process.
Several complex, multifaceted implementation strat-
egies have shown to improve diabetes care in experi-
mental settings but they are seldom replicated or
sustained in daily practice [4,20,72]. Healthcare provi-
ders have many competing demands, and especially
small healthcare organisations have few resources for
conducting complex interventions [72]. Despite positive
attitudes that healthcare providers and patients express
regarding shared goal-setting and decision-making, they
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appear to have difficulties to translate these intentions
into practice [15,42,45]. Simple tools that can help to
structure and prioritise treatment goals and plans are
needed. The PORTDA-diab developed in this study can
be characterised as a minimal-intensity strategy that
requires little extra time to conduct in a normal practice
setting. Strategies that can prepare patients better for a
consultation on disease management have the potential
of being very cost-effective.
The decision aid is developed building on existing
knowledge and following most of the recommendations
for high quality decision aids [56]. To the best of our
knowledge, there have been no rigorous studies evaluat-
ing the effects of patient-oriented treatment decision
aids that deal with multiple treatment goals and plans
for individual patients. Recently, two newly developed
decision aids dealing with multifactorial cardiovascular
treatment have been pilot tested, showing acceptability
and feasibility of using such decision aids in primary
care settings [27,28].
The outcome measures in our study have been chosen
to provide detailed information on the process and out-
comes of the intervention. Changes in patients’ empower-
ment and perceptions will be measured with structured
questionnaires. Data on actual management and clinical
outcomes will be assessed up to 6 months after the inter-
vention allowing for delayed actions. The study is not
designed or powered to assess any long-term outcomes
regarding morbidity or mortality. By inclusion of the pre-
dicted absolute coronary heart disease risk as secondary
outcome measure, however, we will be able to draw con-
clusions on potential benefits on long-term outcomes.
There is scarce information on how positive and nega-
tive effects of patient-oriented decision aids may differ
for different patients [18,73]. Diabetes patients will typic-
ally differ in the severity and duration of their disease,
the number of co-morbid conditions, and the number of
medications they need. Patients may also differ in ex-
periencing negative feelings when confronted with per-
sonal risk information. Some patients have trouble with
the quantitative scoring of risk and the clinical focus on
numerical treatment goals instead of functional goals
[8,15,17,42,57,58,74]. Patients can furthermore differ in
their preferences and abilities to participate in treatment
decision-making [8,58,74], and in their information
needs. This study aims to include a heterogeneous group
of patients with type 2 diabetes. By examining inter-
action effects of the intervention in relation to inter-
individual differences, the study can provide insights into
the utility and feasibility of using this type of decision
support in various patient populations. The population
is, however, restricted on specific clinical characteristics,
such as age at diagnosis (≤65 years), and on cognitive
and reading abilities.
The study will specifically address two matters of
interest, which can contribute to the further develop-
ment of interactive (web-based) programs for the man-
agement of chronic diseases [75]. Many computer and
web-based decision aids are being developed but there
are concerns that not all patients may be able to use
such systems. This study will provide information on dif-
ferential effects of using a paper-based as compared to a
computer-based decision aid, looking particularly at pa-
tient demographics, such as age, gender, educational
level, and socioeconomic status. There are also questions
regarding reframing messages about benefits of treat-
ment to the perspective of the patient [57,76]. Most
patient decision aids formulate outcomes in terms of
major clinical endpoints, such as the risk of dying or - in
case of cardiovascular risk management - the risk of get-
ting a myocardial infarction. This study will assess what
the effects can be of giving additional information on
other outcomes that some patients might consider of
more importance.
A possible limitation of our study may be selection
bias of participating practices. They may represent a
group that is more open to shared decision-making.
Since this study aims to develop and pilot an innovative
strategy, we feel this is not a major drawback. Further-
more, the short duration of the intervention may limit
the potential of the decision aid. Although the interven-
tion allows for a follow-up consultation, it is possible
that repeated use of the decision aid can enhance its ef-
fect. We will be able to use the results from the process
evaluation to make adjustments or recommendations for
further implementation of treatment decision aids in
practice. If this aid is found to be helpful, it can be
implemented and tested on a larger scale. The approach
can also be translated to other areas of chronic disease
management where patients are confronted with mul-
tiple treatment goals and plans.
Trial status
Patient recruitment continued until September 2012.
Baseline data collection will be completed in 2012. Out-
come data collection will be completed in 2013.
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